proteomics
Acrivon Therapeutics to Study CHK1/2 Inhibitor ACR-368, Predictive Diagnostic in Phase II Trial
The trial will enroll patients with ovarian, endometrial, and urothelial cancer, and stratify them for treatment using Acrivon's OncoSignature proteomic diagnostic.
OncoHost Raises $35M in Series C Financing
The Israeli firm will use the funds to expand its PROPHETIC trial and support the US commercial launch of the Prophet platform.
European Precision Oncology Multi-Omics Project Advances With Biognosys Mass Spec Technology
Biognosys will help researchers in the Cancer Scout project create digital biopsies from genomic, proteomic, and pathology data to inform personalized treatment.
Israeli Startup OncoHost Eyeing 2022 Commercial Launch of Immunotherapy Response Prediction Test
Premium
The firm is validating its proteomics- and machine learning-based Prophet platform and setting up US operations in anticipation of a commercial launch next year.
Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study
Researchers identified several pre-treatment markers that correlated with T-cell expansion and could be predictive of response to a PD1 inhibitor.